Clinical trial
Efficacy and Safety Study of ZK219477 in Patients With Recurrent Ovarian Cancer
NCT00246688 · Bayer, Industry · Completed
Key facts
| NCT number | NCT00246688 |
|---|---|
| Title | Efficacy and Safety Study of ZK219477 in Patients With Recurrent Ovarian Cancer |
| Official title | Randomized, Multicenter, Prospective Two-arm, Open-label Phase II Study to Investigate the Efficacy and Safety of Two ZK219477 i.v. Infusions (3-hour Infusion of 16mg/m2 Versus 0.5-hour Infusion of 16 mg/m2) in Patients With Recurrent Ovarian Cancer Progressing During, or Within 6 Months of the End… |
| Lead sponsor | Bayer, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Ovarian Neoplasms |
| Intervention type | Drug |
| Interventions | Sagopilone (BAY86-5302, ZK219477) |
| Enrollment | 63 |
| Start date | Nov 1, 2005 |
| Primary completion | Jun 1, 2007 |
| Completion | Jun 1, 2007 |
| First posted | Oct 31, 2005 |
| Last update posted | Dec 31, 2015 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: